Form 8-K - Current report:
SEC Accession No. 0001104659-25-089272
Filing Date
2025-09-11
Accepted
2025-09-11 08:40:41
Documents
15
Period of Report
2025-09-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2525854d1_8k.htm   iXBRL 8-K 32610
2 EXHIBIT 4.1 tm2525854d1_ex4-1.htm EX-4.1 93995
3 EXHIBIT 10.1 tm2525854d1_ex10-1.htm EX-10.1 67072
4 EXHIBIT 99.1 tm2525854d1_ex99-1.htm EX-99.1 9929
  Complete submission text file 0001104659-25-089272.txt   419201

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA sls-20250910.xsd EX-101.SCH 3041
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE sls-20250910_lab.xml EX-101.LAB 34239
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sls-20250910_pre.xml EX-101.PRE 22377
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2525854d1_8k_htm.xml XML 3688
Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)